Mutations Involved in Premature-Ageing Syndromes

References

• Coppedè F. Premature aging syndrome. Adv Exp Med Biol. 2012;724:317–331.
   PubMed Web of Science ®Google Scholar
• Lessel D, Kubisch C. Hereditary syndromes with signs of premature aging. Dtsch Arztebl Int. 2019;116(29–30):489–496. doi:10.3238/arztebl.2019.0489
   Web of Science ®Google Scholar
• Schnabel F, Kornak U, Wollnik B. Premature aging disorders: a clinical and genetic compendium. Clin Genet. 2021;99(1):3–28. doi:10.1111/cge.13837
   PubMed Web of Science ®Google Scholar
• Grelet M, Blanck V, Sigaudy S, et al. Outcomes of 4 years of molecular genetic diagnosis on a panel of genes involved in premature aging syndromes, including laminopathies and related disorders. Orphanet J Rare Dis. 2019;14(1):288. doi:10.1186/s13023-019-1189-z
   Web of Science ®Google Scholar
• Coppedè F. The epidemiology of premature aging and associated comorbidities. Clin Interv Aging. 2013;8:1023–1032. doi:10.2147/CIA.S37213
   Web of Science ®Google Scholar
• Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford progeria syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews^® (Internet). Seattle: University of Washington; 2019. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK1121/#top. Accessed March 15, 2021.
   Google Scholar
• Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423(6937):293–298. doi:10.1038/nature01629
   PubMed Web of Science ®Google Scholar
• De Sandre-giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003;300(5628):2055. doi:10.1126/science.1084125
   PubMed Web of Science ®Google Scholar
• Goldman RD, Shumaker DK, Erdos MR, et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson–Gilford progeria syndrome. Proc Natl Acad Sci USA. 2004;101(24):8963–8968. doi:10.1073/pnas.0402943101
   PubMed Web of Science ®Google Scholar
• Arancio W, Pizzolanti G, Genovese SI, Pitrone M, Giordano C. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review. Gerontology. 2014;60(3):197–203. doi:10.1159/000357206
   PubMed Web of Science ®Google Scholar
• Köhler F, Bormann F, Raddatz G, et al. Epigenetic deregulation of lamina-associated domains in Hutchinson-Gilford progeria syndrome. Genome Med. 2020;12(1):46. doi:10.1186/s13073-020-00749-y
   Web of Science ®Google Scholar
• Gonzalo S, Kreienkamp R. DNA repair defects and genome instability in Hutchinson-Gilford progeria syndrome. Curr Opin Cell Biol. 2015;34:75–83. doi:10.1016/j.ceb.2015.05.007
   PubMed Web of Science ®Google Scholar
• The UMD-LMNA mutations database; January 31, 2020. Available from: https://www.umd.be/LMNA/. Accessed March 15, 2021.
   Google Scholar
• Barrowman J, Wiley PA, Hudon-Miller SE, Hrycyna CA, Michaelis S. Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity. Hum Mol Genet. 2012;21(18):4084–4093. doi:10.1093/hmg/dds233
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Fryns JP, Auchus RJ, Garg A. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet. 2003;12(16):1995–2001. doi:10.1093/hmg/ddg213
   PubMed Web of Science ®Google Scholar
• Navarro CL, De Sandre-giovannoli A, Bernard R, et al. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet. 2004;13(20):2493–2503. doi:10.1093/hmg/ddh265
   Web of Science ®Google Scholar
• Navarro CL, Esteves-Vieira V, Courrier S, et al. New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update. Eur J Hum Genet. 2014;22(8):1002–1011. doi:10.1038/ejhg.2013.258
   PubMed Web of Science ®Google Scholar
• Puente XS, Quesada V, Osorio FG, et al. Exome sequencing and functional analysis identifies BANF1 mutation as the cause of a hereditary progeroid syndrome. Am J Hum Genet. 2011;88(5):650–656. doi:10.1016/j.ajhg.2011.04.010
   PubMed Web of Science ®Google Scholar
• Cabanillas R, Cadiñanos J, Villameytide JA, et al. Néstor-Guillermo progeria syndrome: a novel premature aging condition with early onset and chronic development caused by BANF1 mutations. Am J Med Genet A. 2011;155A(11):2617–2625. doi:10.1002/ajmg.a.34249
   PubMed Web of Science ®Google Scholar
• Torras-Llort M, Medina-Giró S, Escudero-Ferruz P, et al. A fraction of barrier-to-autointegration factor (BAF) associates with centromeres and controls mitosis progression. Commun Biol. 2020;3(1):454. doi:10.1038/s42003-020-01182-y
   PubMed Web of Science ®Google Scholar
• Romero-Bueno R, de la Cruz Ruiz P, Artal-Sanz M, Askjaer P, Dobrzynska A. Nuclear organization in stress and aging. Cells. 2019;8(7):664. doi:10.3390/cells8070664
   Web of Science ®Google Scholar
• Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015;132:249–264.
   PubMedGoogle Scholar
• Coppedè F. Premature aging syndrome. In: Ram JL, Conn M, editors. Conn’s Handbook of Models for Human Aging. 2nd ed. Academic Press; 2018:21–34.
   Google Scholar
• The progeria research foundation. MA, USA: Peabody. Available from: https://www.progeriaresearch.org/. Accessed March 15, 2021.
   Google Scholar
• Kandhaya-Pillai R, Hisama FM, Bucks SA, et al. Novel LMNA mutations in Greek and Myanmar patients with progeroid features and cardiac manifestations. Aging Pathobiol Ther. 2020;2(2):101–105. doi:10.31491/APT.2020.06.021
   Google Scholar
• Starke S, Meinke P, Camozzi D, et al. Progeroid laminopathy with restrictive dermopathy-like features caused by an isodisomic LMNA mutation p.R435C. Aging (Albany NY). 2013;5(6):445–459. doi:10.18632/aging.100566
   Google Scholar
• Navarro CL, Cadiñanos J, De Sandre-giovannoli A, et al. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum Mol Genet. 2005;14(11):1503–1513. doi:10.1093/hmg/ddi159
   Web of Science ®Google Scholar
• Moulson CL, Go G, Gardner JM, et al. Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest Dermatol. 2005;125(5):913–919. doi:10.1111/j.0022-202X.2005.23846.x
   PubMed Web of Science ®Google Scholar
• Denecke J, Brune T, Feldhaus T, et al. A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS. Hum Mutat. 2006;27(6):524–531. doi:10.1002/humu.20315
   Web of Science ®Google Scholar
• Cenni V, D’Apice MR, Garagnani P, et al. Mandibuloacral dysplasia: a premature ageing disease with aspects of physiological ageing. Ageing Res Rev. 2018;42:1–13. doi:10.1016/j.arr.2017.12.001
   PubMed Web of Science ®Google Scholar
• Novelli G, Muchir A, Sangiuolo F, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet. 2002;71(2):426–431. doi:10.1086/341908
   PubMed Web of Science ®Google Scholar
• Ben Yaou R, Navarro C, Quijano-Roy S, et al. Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation. Eur J Hum Genet. 2011;19(6):647–654. doi:10.1038/ejhg.2010.256
   PubMed Web of Science ®Google Scholar
• Hitzert MM, van der Crabben SN, Baldewsingh G, et al. Mandibuloacral dysplasia type B (MADB): a cohort of eight patients from suriname with a homozygous founder mutation in ZMPSTE24 (FACE1), clinical diagnostic criteria and management guidelines. Orphanet J Rare Dis. 2019;14(1):294. doi:10.1186/s13023-019-1269-0
   Web of Science ®Google Scholar
• Spear ED, Hsu ET, Nie L, Carpenter EP, Hrycyna CA, Michaelis S. ZMPSTE24 missense mutations that cause progeroid diseases decrease prelamin A cleavage activity and/or protein stability. Dis Model Mech. 2018;11(7):dmm033670. doi:10.1242/dmm.033670
   PubMed Web of Science ®Google Scholar
• Filesi I, Gullotta F, Lattanzi G, et al. Alterations of nuclear envelope and chromatin organization in mandibuloacral dysplasia, a rare form of laminopathy. Physiol Genomics. 2005;23(2):150–158. doi:10.1152/physiolgenomics.00060.2005
   Web of Science ®Google Scholar
• Fisher HG, Patni N, Scheuerle AE. An additional case of Nestor-Guillermo progeria syndrome diagnosed in early childhood. Am J Med Genet A. 2020;182(10):2399–2402. doi:10.1002/ajmg.a.61777
   Web of Science ®Google Scholar
• Paquet N, Box JK, Ashton NW, et al. Nestor-Guillermo progeria syndrome: a biochemical insight into barrier-to-autointegration factor 1, alanine 12 threonine mutation. BMC Mol Biol. 2014;15(1):27. doi:10.1186/s12867-014-0027-z
   Web of Science ®Google Scholar
• Bolderson E, Burgess JT, Li J, et al. Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage. Nat Commun. 2019;10(1):5501. doi:10.1038/s41467-019-13167-5
   PubMed Web of Science ®Google Scholar
• Weedon MN, Ellard S, Prindle MJ, et al. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet. 2013;45(8):947–950. doi:10.1038/ng.2670
   PubMed Web of Science ®Google Scholar
• Elouej S, Harhouri K, Le Mao M, et al. Loss of MTX2 causes mandibuloacral dysplasia and links mitochondrial dysfunction to altered nuclear morphology. Nat Commun. 2020;11(1):4589. doi:10.1038/s41467-020-18146-9
   Web of Science ®Google Scholar
• Shastry S, Simha V, Godbole K, et al. A novel syndrome of mandibular hypoplasia, deafness, and progeroid features associated with lipodystrophy, undescended testes, and male hypogonadism. J Clin Endocrinol Metab. 2010;95(10):E192–197. doi:10.1210/jc.2010-0419
   PubMed Web of Science ®Google Scholar
• Pelosini C, Martinelli S, Ceccarini G, et al. Identification of a novel mutation in the polymerase delta 1 (POLD1) gene in a lipodystrophic patient affected by mandibular hypoplasia, deafness, progeroid features (MDPL) syndrome. Metabolism. 2014;63(11):1385–1389. doi:10.1016/j.metabol.2014.07.010
   PubMed Web of Science ®Google Scholar
• Reinier F, Zoledziewska M, Hanna D. Mandibular hypoplasia, deafness, progeroid features and lipodystrophy (MDPL) syndrome in the context of inherited lipodystrophies. Metabolism. 2015;64(11):1530–1540. doi:10.1016/j.metabol.2015.07.022
   Web of Science ®Google Scholar
• Lessel D, Hisama FM, Szakszon K, et al. POLD1 germline mutations in patients initially diagnosed with Werner syndrome. Hum Mutat. 2015;36(11):1070–1079. doi:10.1002/humu.22833
   PubMed Web of Science ®Google Scholar
• Okada A, Kohmoto T, Naruto T, et al. The first Japanese patient with mandibular hypoplasia, deafness, progeroid features and lipodystrophy diagnosed via POLD1 mutation detection. Hum Genome Var. 2017;4(1):17031. doi:10.1038/hgv.2017.31
   Google Scholar
• Ajluni N, Meral R, Neidert AH, et al. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol (Oxf). 2017;86(5):698–707. doi:10.1111/cen.13311
   PubMed Web of Science ®Google Scholar
• Elouej S, Beleza-Meireles A, Caswell R, et al. Exome sequencing reveals a de novo POLD1 mutation causing phenotypic variability in mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome (MDPL). Metabolism. 2017;71:213–225. doi:10.1016/j.metabol.2017.03.011
   PubMed Web of Science ®Google Scholar
• Sasaki H, Yanagi K, Ugi S, et al. Definitive diagnosis of mandibular hypoplasia, deafness, progeroid features and lipodystrophy (MDPL) syndrome caused by a recurrent de novo mutation in the POLD1 gene. Endocr J. 2018;65(2):227–238. doi:10.1507/endocrj.EJ17-0287
   Web of Science ®Google Scholar
• Wang LR, Radonjic A, Dilliott AA, McIntyre AD, Hegele RA. A de novo POLD1 mutation associated with mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome in a family with Werner syndrome. J Investig Med High Impact Case Rep. 2018;6:2324709618786770. doi:10.1177/2324709618786770
   Web of Science ®Google Scholar
• Wang XW, Lu LY, Xie Y, Yu XJ. A Chinese girl with mandibular hypoplasia, deafness, progeroid features, and lipodystrophy (MDPL) diagnosed via POLD1 mutation detection. Chin Med J (Engl). 2020;133(16):2009–2011. doi:10.1097/CM9.0000000000000986
   Web of Science ®Google Scholar
• Yu PT, Luk HM, Mok MT, Lo FI. Evolving clinical manifestations of mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome: from infancy to adulthood in a 31-year-old woman. Am J Med Genet A. 2021;185(3):995–998. doi:10.1002/ajmg.a.62035
   Web of Science ®Google Scholar
• Murdocca M, Spitalieri P, De Masi C, et al. Functional analysis of POLD1 p.ser605del variant: the aging phenotype of MDPL syndrome is associated with an impaired DNA repair capacity. Aging (Albany NY). 2021;13(4):4926–4945. doi:10.18632/aging.202680
   Google Scholar
• Ono K, Wang X, Kim SO, Armstrong LC, Bornstein P, Han J. Metaxin deficiency alters mitochondrial membrane permeability and leads to resistance to TNF-induced cell killing. Protein Cell. 2010;1(2):161–173. doi:10.1007/s13238-010-0017-y
   Web of Science ®Google Scholar
• Rivera-Torres J, Acín-Perez R, Cabezas-Sánchez P, et al. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture. J Proteomics. 2013;91:466–477. doi:10.1016/j.jprot.2013.08.008
   PubMed Web of Science ®Google Scholar
• Sieprath T, Corne TD, Nooteboom M, et al. Sustained accumulation of prelamin A and depletion of lamin A/C both cause oxidative stress and mitochondrial dysfunction but induce different cell fates. Nucleus. 2015;6(3):236–246. doi:10.1080/19491034.2015.1050568
   PubMed Web of Science ®Google Scholar
• Coppedè F, Migliore L. DNA repair in premature aging disorders and neurodegeneration. Curr Aging Sci. 2010;3(1):3–19. doi:10.2174/1874609811003010003
   Google Scholar
• Petr MA, Tulika T, Carmona-Marin LM, Scheibye-Knudsen M. Protecting the aging genome. Trends Cell Biol. 2020;30(2):117–132. doi:10.1016/j.tcb.2019.12.001
   Web of Science ®Google Scholar
• Hisama FM, Oshima J, Martin GM. How research on human progeroid and antigeroid syndromes can contribute to the longevity dividend initiative. Cold Spring Harb Perspect Med. 2016;6(4):a025882. doi:10.1101/cshperspect.a025882
   Web of Science ®Google Scholar
• Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner’s syndrome gene. Science. 1996;272(5259):258–262. doi:10.1126/science.272.5259.258
   PubMed Web of Science ®Google Scholar
• Muftuoglu M, Oshima J, von Kobbe C, Cheng WH, Leistritz DF, Bohr VA. The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. Hum Genet. 2008;124(4):369–377. doi:10.1007/s00439-008-0562-0
   Web of Science ®Google Scholar
• Oshima J, Sidorova JM, Monnat RJ Jr. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev. 2017;33:105–114. doi:10.1016/j.arr.2016.03.002
   PubMed Web of Science ®Google Scholar
• Oshima J, Martin GM, Hisama FM. Werner syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews^® (Internet). Seattle: University of Washington; 2016. Available from: www.ncbi.nlm.nih.gov/books/NBK1514/. Accessed March 15, 2021.
   Google Scholar
• Goto M, Ishikawa Y, Sugimoto M, Furuichi Y. Werner syndrome: a changing pattern of clinical manifestations in Japan (1917~2008). Biosci Trends. 2013;7(1):13–22.
   Web of Science ®Google Scholar
• Yokote K, Chanprasert S, Lee L. WRN mutation update: mutation spectrum, patient registries, and translational prospects. Hum Mutat. 2017;38(1):7–15. doi:10.1002/humu.23128
   Web of Science ®Google Scholar
• Satoh M, Imai M, Sugimoto M, Goto M, Furuichi Y. Prevalence of Werner’s syndrome heterozygotes in Japan. Lancet. 1999;353(9166):1766. doi:10.1016/S0140-6736(98)05869-3
   Web of Science ®Google Scholar
• Masala MV, Scapaticci S, Olivieri C, et al. Epidemiology and clinical aspects of Werner’s syndrome in North Sardinia: description of a cluster. Eur J Dermatol. 2007;17(3):213–216. doi:10.1684/ejd.2007.0155
   Web of Science ®Google Scholar
• Friedrich K, Lee L, Leistritz DF, et al. WRN mutations in Werner syndrome patients: genomic rearrangements, unusual intronic mutations and ethnic-specific alterations. Hum Genet. 2010;128(1):103–111. doi:10.1007/s00439-010-0832-5
   Web of Science ®Google Scholar
• Saha B, Lessel D, Nampoothiri S, et al. Ethnic-specific WRN mutations in South Asian Werner syndrome patients: potential founder effect in patients with Indian or Pakistani ancestry. Mol Genet Genomic Med. 2013;1(1):7–14. doi:10.1002/mgg3.1
   Google Scholar
• Uhrhammer NA, Lafarge L, Dos Santos L, et al. Werner syndrome and mutations of the WRN and LMNA genes in France. Hum Mutat. 2006;27(7):718–719. doi:10.1002/humu.9435
   Web of Science ®Google Scholar
• Huang S, Lee L, Hanson NB, et al. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat. 2006;27(6):558–567. doi:10.1002/humu.20337
   Web of Science ®Google Scholar
• The Werner syndrome mutational database. Seattle, WA, USA: Department of Pathology, University of Washington. Available from: http://www.pathology.washington.edu/research/werner/database/. Accessed March 15, 2021.
   Google Scholar
• Melcher R, von Golitschek R, Steinlein C, et al. Spectral karyotyping of Werner syndrome fibroblast cultures. Cytogenet Cell Genet. 2000;91(1–4):180–185. doi:10.1159/000056841
   Google Scholar
• The international registry of Werner syndrome. Seattle, WA, USA: Department of Pathology, University of Washington; January 4, 2019. Available from: http://www.pathology.washington.edu/research/werner/registry/gene.html. Accessed March 15, 2021.
   Google Scholar
• Chen L, Lee L, Kudlow BA, et al. LMNA mutations in atypical Werner’s syndrome. Lancet. 2003;362(9382):440–445. doi:10.1016/S0140-6736(03)14069-X
   PubMed Web of Science ®Google Scholar
• Lessel D, Vaz B, Halder S, et al. Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet. 2014;46(11):1239–1244. doi:10.1038/ng.3103
   PubMed Web of Science ®Google Scholar
• Lopez-Mosqueda J, Maddi K, Prgomet S, et al. SPRTN is a mammalian DNA-binding metalloprotease that resolves DNA-protein crosslinks. Elife. 2016;5:e21491. doi:10.7554/eLife.21491
   Web of Science ®Google Scholar
• Lessel D, Saha B, Hisama F, et al. Atypical Aicardi-Goutieres syndrome: is the WRN locus a modifier? Am J Med Genet A. 2014;164A(10):2510–2513. doi:10.1002/ajmg.a.36664
   Web of Science ®Google Scholar
• Ellis NA, Groden J, Ye TZ, et al. The Bloom’s syndrome gene product is homologous to RecQ helicases. Cell. 1995;83(4):655–666. doi:10.1016/0092-8674(95)90105-1
   PubMed Web of Science ®Google Scholar
• Kaneko H, Kondo N. Clinical features of Bloom syndrome and function of the causative gene, BLM helicase. Expert Rev Mol Diagn. 2004;4(3):393–401. doi:10.1586/14737159.4.3.393
   PubMed Web of Science ®Google Scholar
• Kitao S, Shimamoto A, Goto M, et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet. 1999;22(1):82–84. doi:10.1038/8788
   PubMed Web of Science ®Google Scholar
• Colombo EA, Locatelli A, Cubells Sánchez L, et al. Rothmund-Thomson syndrome: insights from new patients on the genetic variability underpinning clinical presentation and cancer outcome. Int J Mol Sci. 2018;19(4):1103. doi:10.3390/ijms19041103
   Web of Science ®Google Scholar
• Karikkineth AC, Scheibye-Knudsen M, Fivenson E, Croteau DL, Bohr VA. Cockayne syndrome: clinical features, model systems and pathways. Ageing Res Rev. 2017;33:3–17. doi:10.1016/j.arr.2016.08.002
   PubMed Web of Science ®Google Scholar
• Lehmann J, Seebode C, Martens MC, Emmert S. Xeroderma pigmentosum - facts and perspectives. Anticancer Res. 2018;38(2):1159–1164. doi:10.21873/anticanres.12335
   Web of Science ®Google Scholar
• Rizza ERH, DiGiovanna JJ, Khan SG, Tamura D, Jeskey JD, Kraemer KH. Xeroderma pigmentosum: a model for human premature aging. J Invest Dermatol. 2021;141(4S):S0022-202X(20)32358-7. doi:10.1016/j.jid.2020.11.012
   Web of Science ®Google Scholar
• Ferri D, Orioli D, Botta E. Heterogeneity and overlaps in nucleotide excision repair disorders. Clin Genet. 2020;97(1):12–24. doi:10.1111/cge.13545
   Web of Science ®Google Scholar
• Wambach JA, Wegner DJ, Patni N, et al. Bi-allelic POLR3A loss-of function variants cause autosomal-recessive Wiedemann-Rautenstrauch syndrome. Am J Hum Genet. 2018;103(6):968–975. doi:10.1016/j.ajhg.2018.10.010
   Web of Science ®Google Scholar
• Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature. 1988;336(6199):577–580. doi:10.1038/336577a0
   PubMed Web of Science ®Google Scholar
• Sandoval N, Platzer M, Rosenthal A, et al. Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet. 1999;8(1):69–79. doi:10.1093/hmg/8.1.69
   PubMed Web of Science ®Google Scholar
• AlSabbagh MM. Dyskeratosis congenita: a literature review. J Dtsch Dermatol Ges. 2020;18(9):943–967.
   Google Scholar
• Ehmke N, Graul-Neumann L, Smorag L, et al. De novo mutations in SLC25A24 cause a craniosynostosis syndrome with hypertrichosis, progeroid appearance, and mitochondrial dysfunction. Am J Hum Genet. 2017;101(5):833–843. doi:10.1016/j.ajhg.2017.09.016
   Web of Science ®Google Scholar
• Reversade B, Escande-Beillard N, Dimopoulou A, et al. Mutations in PYCR1 cause cutis laxa with progeroid features. Nat Genet. 2009;41(9):1016–1021. doi:10.1038/ng.413
   PubMed Web of Science ®Google Scholar
• Passarge E, Robinson PN, Graul-Neumann LM. Marfanoid–progeroid–lipodystrophy syndrome: a newly recognized fibrillinopathy. Eur J Hum Genet. 2016;24(9):1244–1247. doi:10.1038/ejhg.2016.6
   Web of Science ®Google Scholar
• Johnston JJ, Sanchez-Contreras MY, Keppler-Noreuil KM, et al. A point mutation in PDGFRB causes autosomal-dominant Penttinen syndrome. Am J Hum Genet. 2015;97(3):465–474. doi:10.1016/j.ajhg.2015.07.009
   Web of Science ®Google Scholar
• Dyment DA, Smith AC, Alcantara D, et al. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet. 2013;93(1):158–166. doi:10.1016/j.ajhg.2013.06.005
   PubMed Web of Science ®Google Scholar
• National organization for rare disorders. Danbury, CT, USA. Available from: https://rarediseases.org/. Accessed May 4, 2021.
   Google Scholar
• Dhillon S. Lonafarnib: first approval. Drugs. 2021;81(2):283–289. doi:10.1007/s40265-020-01464-z
   PubMed Web of Science ®Google Scholar
• Gordon LB, Kleinman ME, Massaro J, et al. Clinical trial of the protein farnesylation inhibitors lonafarnib, pravastatin, and zoledronic acid in children with Hutchinson-Gilford Progeria syndrome. Circulation. 2016;134(2):114–125. doi:10.1161/CIRCULATIONAHA.116.022188
   PubMed Web of Science ®Google Scholar
• Cao K, Graziotto JJ, Blair CD. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med. 2011;3(89):89ra58. doi:10.1126/scitranslmed.3002346
   PubMed Web of Science ®Google Scholar
• DuBose AJ, Lichtenstein ST, Petrash NM, et al. Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc Natl Acad Sci U S A. 2018;115(16):4206–4211. doi:10.1073/pnas.1802811115
   Web of Science ®Google Scholar
• Santiago-Fernández O, Osorio FG, Quesada V, et al. Development of a CRISPR/Cas9-based therapy for Hutchinson-Gilford progeria syndrome. Nat Med. 2019;25(3):423–426. doi:10.1038/s41591-018-0338-6
   PubMed Web of Science ®Google Scholar
• Beyret E, Liao HK, Yamamoto M, et al. Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome. Nat Med. 2019;25(3):419–422. doi:10.1038/s41591-019-0343-4
   PubMed Web of Science ®Google Scholar
• Koblan LW, Erdos MR, Wilson C, et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021;589(7843):608–614. doi:10.1038/s41586-020-03086-7
   PubMed Web of Science ®Google Scholar
• Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018;19(12):770–788. doi:10.1038/s41576-018-0059-1
   PubMed Web of Science ®Google Scholar